TG Therapeutics, Inc. which can be found using ticker (TGTX) now have 8 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between 42 and 6 with the average target price sitting at $30.06. Given that the stocks previous close was at $28.58 and the analysts are correct then there would likely be a percentage uptick in value of 5.2%. The day 50 moving average is $22.74 and the 200 moving average now moves to $13.00. The company has a market capitalization of 4.30B. The stock price is currently at: 28.76 USD
The potential market cap would be $4,519,127,893 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 0.06 and a -40.71% return on assets.
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
